In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands

Xiankai Sun, Joonyoung Kim, Arthur E. Martell, Michael J. Welch, Carolyn J. Anderson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Copper-64 (T 1/2=12.7 h; β +: 0.653 MeV, 17.4%; β -: 0.578 MeV, 39%) has applications in positron emission tomography (PET) imaging and radiotherapy, and is conveniently produced on a biomedical cyclotron. Tetraazamacrocyclic ligands are the most widely used bifunctional chelators (BFCs) for attaching copper radionuclides to antibodies and peptides due to their relatively high kinetic stability. In this paper, we evaluated three monooxo-tetraazamacrocyclic ligands with different ring sizes and oxo group positions. H1 [1,4,7,10-tetraazacyclotridecan-11-one], H2 [1,4,8,11-tetraazacyclotetradecan-5-one] and H3 [1,4,7,10-tetraazacyclotridecan- 2-one] were radiolabeled with 64Cu in high radiochemical yields under mild conditions. The three 64Cu-labeled complexes are all +1 charged, as determined by their electrophoretic mobility. While they demonstrated >95% stability in rat serum out to 24 h, both biodistribution and microPET imaging studies revealed high uptake and long retention of the compounds in major clearance organs (e.g., blood, liver and kidney), which suggests that 64Cu dissociated from the complexes in vivo. Of the three complexes, 64Cu-2 +, which has a cyclam backbone (1,4,8,11-tetraazacyclotetradecane), exhibited the lowest nontarget organ accumulation. The data from these studies may invalidate the candidacy of the monooxo-tetraazamacrocyclics as BFCs for copper radiopharmaceuticals. However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications.

Original languageEnglish (US)
Pages (from-to)1051-1059
Number of pages9
JournalNuclear Medicine and Biology
Volume31
Issue number8
DOIs
StatePublished - Nov 2004

Fingerprint

Copper
Ligands
Radiopharmaceuticals
Chelating Agents
Cyclotrons
Radioisotopes
Positron-Emission Tomography
Radiotherapy
Kidney
Peptides
Antibodies
Liver
Serum
cyclam

Keywords

  • Biodistribution
  • Copper-64
  • Macrocycle
  • MicroPET

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands. / Sun, Xiankai; Kim, Joonyoung; Martell, Arthur E.; Welch, Michael J.; Anderson, Carolyn J.

In: Nuclear Medicine and Biology, Vol. 31, No. 8, 11.2004, p. 1051-1059.

Research output: Contribution to journalArticle

Sun, Xiankai ; Kim, Joonyoung ; Martell, Arthur E. ; Welch, Michael J. ; Anderson, Carolyn J. / In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands. In: Nuclear Medicine and Biology. 2004 ; Vol. 31, No. 8. pp. 1051-1059.
@article{fdc7bd705f504cc1a3750a19024a2c14,
title = "In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands",
abstract = "Copper-64 (T 1/2=12.7 h; β +: 0.653 MeV, 17.4{\%}; β -: 0.578 MeV, 39{\%}) has applications in positron emission tomography (PET) imaging and radiotherapy, and is conveniently produced on a biomedical cyclotron. Tetraazamacrocyclic ligands are the most widely used bifunctional chelators (BFCs) for attaching copper radionuclides to antibodies and peptides due to their relatively high kinetic stability. In this paper, we evaluated three monooxo-tetraazamacrocyclic ligands with different ring sizes and oxo group positions. H1 [1,4,7,10-tetraazacyclotridecan-11-one], H2 [1,4,8,11-tetraazacyclotetradecan-5-one] and H3 [1,4,7,10-tetraazacyclotridecan- 2-one] were radiolabeled with 64Cu in high radiochemical yields under mild conditions. The three 64Cu-labeled complexes are all +1 charged, as determined by their electrophoretic mobility. While they demonstrated >95{\%} stability in rat serum out to 24 h, both biodistribution and microPET imaging studies revealed high uptake and long retention of the compounds in major clearance organs (e.g., blood, liver and kidney), which suggests that 64Cu dissociated from the complexes in vivo. Of the three complexes, 64Cu-2 +, which has a cyclam backbone (1,4,8,11-tetraazacyclotetradecane), exhibited the lowest nontarget organ accumulation. The data from these studies may invalidate the candidacy of the monooxo-tetraazamacrocyclics as BFCs for copper radiopharmaceuticals. However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications.",
keywords = "Biodistribution, Copper-64, Macrocycle, MicroPET",
author = "Xiankai Sun and Joonyoung Kim and Martell, {Arthur E.} and Welch, {Michael J.} and Anderson, {Carolyn J.}",
year = "2004",
month = "11",
doi = "10.1016/j.nucmedbio.2004.08.011",
language = "English (US)",
volume = "31",
pages = "1051--1059",
journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands

AU - Sun, Xiankai

AU - Kim, Joonyoung

AU - Martell, Arthur E.

AU - Welch, Michael J.

AU - Anderson, Carolyn J.

PY - 2004/11

Y1 - 2004/11

N2 - Copper-64 (T 1/2=12.7 h; β +: 0.653 MeV, 17.4%; β -: 0.578 MeV, 39%) has applications in positron emission tomography (PET) imaging and radiotherapy, and is conveniently produced on a biomedical cyclotron. Tetraazamacrocyclic ligands are the most widely used bifunctional chelators (BFCs) for attaching copper radionuclides to antibodies and peptides due to their relatively high kinetic stability. In this paper, we evaluated three monooxo-tetraazamacrocyclic ligands with different ring sizes and oxo group positions. H1 [1,4,7,10-tetraazacyclotridecan-11-one], H2 [1,4,8,11-tetraazacyclotetradecan-5-one] and H3 [1,4,7,10-tetraazacyclotridecan- 2-one] were radiolabeled with 64Cu in high radiochemical yields under mild conditions. The three 64Cu-labeled complexes are all +1 charged, as determined by their electrophoretic mobility. While they demonstrated >95% stability in rat serum out to 24 h, both biodistribution and microPET imaging studies revealed high uptake and long retention of the compounds in major clearance organs (e.g., blood, liver and kidney), which suggests that 64Cu dissociated from the complexes in vivo. Of the three complexes, 64Cu-2 +, which has a cyclam backbone (1,4,8,11-tetraazacyclotetradecane), exhibited the lowest nontarget organ accumulation. The data from these studies may invalidate the candidacy of the monooxo-tetraazamacrocyclics as BFCs for copper radiopharmaceuticals. However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications.

AB - Copper-64 (T 1/2=12.7 h; β +: 0.653 MeV, 17.4%; β -: 0.578 MeV, 39%) has applications in positron emission tomography (PET) imaging and radiotherapy, and is conveniently produced on a biomedical cyclotron. Tetraazamacrocyclic ligands are the most widely used bifunctional chelators (BFCs) for attaching copper radionuclides to antibodies and peptides due to their relatively high kinetic stability. In this paper, we evaluated three monooxo-tetraazamacrocyclic ligands with different ring sizes and oxo group positions. H1 [1,4,7,10-tetraazacyclotridecan-11-one], H2 [1,4,8,11-tetraazacyclotetradecan-5-one] and H3 [1,4,7,10-tetraazacyclotridecan- 2-one] were radiolabeled with 64Cu in high radiochemical yields under mild conditions. The three 64Cu-labeled complexes are all +1 charged, as determined by their electrophoretic mobility. While they demonstrated >95% stability in rat serum out to 24 h, both biodistribution and microPET imaging studies revealed high uptake and long retention of the compounds in major clearance organs (e.g., blood, liver and kidney), which suggests that 64Cu dissociated from the complexes in vivo. Of the three complexes, 64Cu-2 +, which has a cyclam backbone (1,4,8,11-tetraazacyclotetradecane), exhibited the lowest nontarget organ accumulation. The data from these studies may invalidate the candidacy of the monooxo-tetraazamacrocyclics as BFCs for copper radiopharmaceuticals. However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications.

KW - Biodistribution

KW - Copper-64

KW - Macrocycle

KW - MicroPET

UR - http://www.scopus.com/inward/record.url?scp=10644230282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644230282&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2004.08.011

DO - 10.1016/j.nucmedbio.2004.08.011

M3 - Article

C2 - 15607487

AN - SCOPUS:10644230282

VL - 31

SP - 1051

EP - 1059

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 8

ER -